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Abstract
Backgound: Alveolarization requires coordinated extracellular matrix remodeling, a process in which matrix metallopro-
teinases (MMPs) play an important role. We postulated that polymorphisms in MMP genes might affect MMP function in
preterm lungs and thus influence the risk of bronchopulmonary dysplasia (BPD).
Methods and Findings: Two hundred and eighty-four consecutive neonates with a gestational age of ,28 weeks were
included in this prospective study. Forty-five neonates developed BPD. Nine single-nucleotide polymorphisms (SNPs) were
sought in the MMP2, MMP14 and MMP16 genes. After adjustment for birth weight and ethnic origin, the TT genotype of
MMP16 C/T (rs2664352) and the GG genotype of MMP16 A/G (rs2664349) were found to protect from BPD. These genotypes
were also associated with a smaller active fraction of MMP2 and with a 3-fold-lower MMP16 protein level in tracheal
aspirates collected within 3 days after birth. Further evaluation of MMP16 expression during the course of normal human
and rat lung development showed relatively low expression during the canalicular and saccular stages and a clear increase
in both mRNA and protein levels during the alveolar stage. In two newborn rat models of arrested alveolarization the lung
MMP16 mRNA level was less than 50% of normal.
Conclusions: MMP16 may be involved in the development of lung alveoli. MMP16 polymorphisms appear to influence not
only the pulmonary expression and function of MMP16 but also the risk of BPD in premature infants.
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Introduction
Despite major advances in the care of very-low-birth-weight
(VLBW) infants, bronchopulmonary dysplasia (BPD) still affects 20
to 40% of survivors [1]. BPD appears to result from arrested lung
development and is characterized by abnormal alveolar septation
and abnormal microvascular maturation [2]. Alveolarization
requires coordination of extracellular matrix remodeling with
epithelial morphogenesis and capillary growth [3]. This process
involves matrix metalloproteinases (MMPs), which are classified
into two major groups according to their subcellular localization:
membrane-type MMPs (MT-MMPs) and secreted MMPs. Among
secreted MMPs, MMP2 is known to play a key role in lung
development and repair after injury. Mice lacking this proteinase
show delayed alveolar development [4], and low MMP2 levels in
tracheal effluent and plasma have been linked to an increased risk
of BPD in infants [5,6]. Type I transmembrane MT-MMPs
participate in the activation of the zymogen form of MMP2 (pro-
MMP2). Among these, MT1-MMP (MMP14) has a major role in
alveolarization. We recently observed a fourfold increase in
MMP14 transcripts in lung fibroblasts during alveolarization [7],
while mice lacking this enzyme have a reduced alveolar surface
area and enlarged air spaces [8,9], although this seems partly
independent of the ability of MMP14 to activate MMP2 [9].
MT3-MMP (MMP16) was originally cloned from a human
placental cDNA library [10]. Although its role in lung develop-
ment has not previously been studied, its ability to localize on the
cell membrane and to activate pro-MMP2 has been clearly
demonstrated. MMP16 is also known to have a splice variant,
consisting of a soluble form lacking the transmembrane domain.
This soluble form can also activate pro-MMP2 [11].
Although exposure of the immature lung to various insults is
thought to play a central role in the onset of BPD, significant
genetic susceptibility to BPD was recently demonstrated in
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genes critical for lung development may therefore have a role in
BPD pathogenesis. We postulated that polymorphisms in MMP
genes might affect MMP function in preterm lung and thereby
influence the risk of BPD at a given gestational age. Indeed, a
single-nucleotide polymorphism (SNP) in the promoter of the
MMP2 gene (21306 C/T) modulates the promoter activity of
MMP2 and has functional significance [13]. In addition, a
haplotype of four MMP14 polymorphisms (2130 T: +256 T:
+6762 C: +7131 C) has been linked to chronic obstructive
pulmonary disease [14]. Finally, the MMP16 splice variant might
potentially be generated by polymorphism of the gene region
coding for the hemopexin domain [11].
Our initial aim in this study was to examine whether any of nine
SNPs in the MMP2, MMP14, and MMP16 genes was associated
with BPD in premature infants, and with the level of MMP2 activity
in tracheal effluents. As we found a significant association with two
SNPs in the MMP16 gene, we further examined the expression of
thisenzymeduring normal humanand rat lung development, and in
newborn rat models of arrested alveolar development.
Methods
Study population
Two hundred and eighty-four neonates with a gestational age of
,28 weeks were included from two neonatal intensive care units
(Creteil and Cochin-Port Royal) between March 2002 and December
2006. All were inborn, and received prophylactic surfactant treatment
immediately after birth, in the delivery room. The mean term was
26.460.1 (SE) weeks (range 23.6–27.9 weeks), and the mean birth
weight was 838611 g (440–1410 g). Perinatal factors susceptible to
influence the risk for BPD were collected: bacteriologically proven
maternofetal infection ; antenatal steroid therapy ; histologically
defined chorioamnionitis ; persistent ductus arteriosus requiring
medical or surgical treatment ; bacteriologically proven postnatal
sepsis ; air leaks. The duration of ventilation support was not analyzed
because of evolving strategies over study time. The diagnosis of BPD
was based on the continued need for oxygen supplementation at a
postmenstrual age (PMA) of 36 weeks, according to the standardized
physiologic test validated by Walsh [15]. The study was approved by
the local ethics committee (CCPPRB Henri Mondor), and written
informed consent was obtained from the parents.
Collection of tracheal secretions
A tracheal aspirate was obtained from 148 of the neonates
immediately after birth (Day 0), before surfactant instillation. One
hundred and five neonates were resampled before extubation, or on
Day 3 when still intubated (mean: 2.560.1 postnatal days). Tracheal
aspiration and sample preparation were performed as previously
described [5,16]. Briefly, suction was performed with a small
catheter and was preceded by instillation of 0.2 ml of isotonic saline.
The aspirate was collected in an infant mucus extractor (Vygon,
Ecouen, France), then diluted in 0.2 ml of isotonic saline, gently
vortexed, and centrifuged at 1200 rpm for 10 min at 4uC. The
supernatant was recovered and stored at 280uC. The dilution factor
induced by this technique is low [5,16], allowing the results to be
expressed per milliliter of supernatant.
Human fetal lung tissue sampling
Lung tissue samples were obtained at autopsy after medical
termination of pregnancyorneonataldeath,with theparentswritten
informed consent. The terminations complied with French legisla-
tion, and the study was approved by our institutional ethics
committee. The fetuses were free of pulmonary diseases and the
samples were histologically normal, with no hypoplasia. Detailed
clinical data on the lung tissue donors have been reported elsewhere
[17]. Fetal age (postconception) is used throughout the paper. The
lung tissues were homogenized in RIPA buffer containing protease
inhibitors (Roche Diagnostics, http://www.roche.com).
Animal models and rat lung tissue
Dated pregnant Sprague-Dawley rats were purchased from
Charles River (Saint Germain sur l’Arbresle, France). The day of
mating was designated day 0 of gestation. Term is 22 days. Lung
tissues were collected between fetal day 18 and postnatal day 21.
Lung tissue from adult rats (8 weeks of age) were also collected.
Fetuses were retrieved by cesarean section under pentobarbital
anesthesia. Lungs from fetuses and pups were immediately frozen
in liquid nitrogen and kept at 280uC until RNA extraction or
immunoblot analysis. Animal experiments complied with the
Guide for Care and Use of Laboratory Animals, and were
authorized by the French Ministry of Agriculture.
In vivo treatment of rat pups
We used two treatments known to induce alveolar growth
disorders in newborn rats, namely hyperoxia and dexamethasone.
Wehavepreviouslyreportedresultingmorphometricalterations[18].
Hyperoxia. Rat pups and their dams were placed in Plexiglas
exposure chambers (Charles River) and run in parallel with either
.95% or 21% (room air) FiO2 from day 0 to day 7. The oxygen
concentration was regularly monitored. Because adult rats have
limited resistance to high O2, the dams were switched daily
between O2-exposed and room air-exposed litters. Pups from two
different litters were mixed so that there were littermates in both
conditions. The chambers were opened for 20 min every day to
switch dams between the air and O2 environments and to clean
the cages. On day 7, the pups were killed by intraperitoneal
sodium pentobarbital injection (70 mg/kg, Ceva, Libourne,
France), and exsanguinated by aortic transsection. The lungs
were immediately placed in liquid nitrogen and kept at 280uC
until RNA or protein extraction.
Dexamethasone (Dex) treatment. Two different litters
were subdivided into three groups of animals, that received an
intraperitoneal injection of 0.1 or 0.5 mg/g/day water-soluble Dex
(Sigma, L’Isle d’Abeau, France), or the vehicle alone (saline,
control group), from birth to day 5. Five animals were used for
each experimental condition. The pups were killed on day 6 as
described above.
MMP2 measurements in tracheal aspirates
A selective ELISA system (R&D Systems, Abingdon, UK) was
used to determine total MMP2 concentrations in tracheal aspirate
supernatants, according to the manufacturer’s instructions. MMP2
activity was evaluated by zymography, as previously described [5].
Supernatants of tracheal aspirates were analyzed by electropho-
resis in 8% (wt/vol) polyacrylamide gels containing 1 mg/ml
gelatin in the presence of SDS in nonreducing conditions. After
electrophoresis, the gels were washed in 2.5% Triton X-100 for
1 h and then rinsed briefly and incubated at 37uC for 24 h in
buffer containing 100 mM Tris-HCl, pH 7.40, and 10 mM
CaCl2. The gels were then stained with Coomassie brillant blue
R250 and restained in a solution of 7.5% acetic acid and 5%
methanol. Enzyme activities in the gel slabs were quantified by
means of image analysis (NIH Image software 1.52 for Macintosh),
on the basis of both the surface area and the intensity of lysis
bands. Results were expressed as arbitrary units (AU) per 24 h per
microliter of supernatant. The total MMP2 level was calculated as
the sum of activities measured at 72 kDa (proenzyme) and 68 kDa
MMP16 Polymorphisms in BPD
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calculated as the activated/total enzyme ratio.
Immunoblot analysis
Immunoblot analysis was applied to supernatants of tracheal
aspirates and to human and rat lung tissue homogenates. Protein
content was assayed in each sample with the Bradford assay. A fixed
amount of total protein (12 mg, 80 mg, and 50 mg for tracheal
aspirates, human lung tissue, and rat lung tissue, respectively) was
electrophoresed on 8 to 10% SDS-polyacrylamide gels then
transferred to polyvinylidene-fluoride membranes (Millipore, Saint-
Quentin en Yvelines, France), then stained with Ponceau S dye
(Sigma, http://www.sigmaaldrich.com). After blocking with 5%
nonfat dry milk in Tris-buffer saline containing 0.1% Tween-20
(TTBS) at room temperature for 90 min, the membranes were
exposed to a rabbit polyclonal antibody against MMP16 (Abcam,
Cambridge, UK), diluted 1:1000 in 2% non fat dry milk in TTBS at
room temperaturefor 2 h. Afterfiverinses inTTBS,themembranes
were incubated for 1 h with a secondary peroxidase-conjugated IgG
antibody (Dako, Trappes, France) diluted 1:2500. The membranes
were then incubated for 1 min in chemiluminescent detection
reagent (ECL, GE Healthcare Life Sciences, Velizy, France) before
exposure to KODAK BioMax MS film for 15 min. NIH image
software was used for densitometric analysis of the blots.
Genotyping
Genomic DNA was extracted from cord-blood leukocytes by using
the Nucleon kit (Amersham). The SNPs studied here are summarized
Table 1. SNPs in the MMP2 and MMP14 genes that had previously
been linked to respiratory diseases wereincluded inthis study, namely
21306 C/T inthe MMP2 gene [19,20], and 2129 G/T, +256 T/C,
+6762 C/G, and +7131 T/C in the MMP14 gene [14]. +6802 G/A
and +6926 C/T SNPs were also included, based on their exonic
location. Two ‘‘tag’’ SNPs (rs2664349 and rs2664352) that determine
a haplotype in the region of the MMP16 gene encoding the
hemopexin domain were selected from HapMap data.
The 21306 C/T genotype was determined by polymerase chain
reaction amplification (PCR) followed by restriction fragment length
polymorphism analysis (RFLP). The forward and reverse primers
were designed with Primer Express software (Applied Biosystems), as
follows: 59-CTT CCT AGG CTG GTC CTT ACT GA-39 and 59-
CTG AGA CCT GAA GAG CTA AAG AGC T-39.T h e
penultimate nucleotide of the reverse primer was modified (G
replaced by C) in order to create a restriction site for Bfa1. PCR was
carried out in a 50-mL volume containing 200 ng of genomic DNA,
5 mLo f1 0 6PCR Rxn Buffer (Invitrogen), 2 mLo f5 0m MM g C l 2
(Invitrogen), 1 mL of nucleotide mix (dNTP 10 mM, Invitrogen), 13
pmolof forward and reverse primer and 1.5units of Taq polymerase
(Recombinant Taq DNA Polymerase, Invitrogen). The thermal
cycling conditions were 94uCf o r5m i n ,3 7c y c l e so f9 4 uCf o r1m i n ,
59uCf o r1 m i na n d7 2 uCf o r1 m i n ,t h e n7 2 uCf o r1 0 m i n .
Enzymatic digestion was carried out in a 20-mL volume containing
3 mL of PCR product, 7.5 units of Bfa1 (New England Biolabs) and
2 mLo f1 6Nebbuffer 4 (New England Biolabs). This mix was then
incubated at 37uC for 4 hours. The size and number of the different
fragments were determined by electrophoretic migration on
ethidium bromide-stained 3% agarose gel. We expected to obtain
one 188-bp fragment for the CC genotype, two fragments (162 and
26 bp) for the TT genotype, and three fragments (188, 162 and
26 bp) for the CT genotype.
The +6762 C/G, +6802 G/A, +6926 C/T and +7131 T/C
genotypes were determined by PCR followed by DNA sequencing.
The forward and reverse primers were designed using Primer
Express software (Applied Biosystems), as follows: 59-GAGGCT-
GAGGGAAGGGACTC-39 and 59-GGGTTTTTGGGTTTAT-
CAGGAAC-39, producing a 590-bp fragment containing the four
SNPs. The PCR mix and thermal cycling conditions were the
same as described above for 21306 C/T. Sequencing was carried
out in a 10-mL volume containing 2 to 5 mL of PCR product, 2 mL
of sequencing mix (Big Dye Terminator 3.1) and 10 pmol of
forward and reverse primer. The thermal cycling conditions were
96uC for 2 min, then 25 cycles of 96uC for 10 sec, 55uC for 5 sec
and 60uC for 1 min. Sequencing was performed by the Molecular
Medicine Unit of Henri Mondor Hospital (IM3). Sequences were
read in our laboratory with Chromas Pro 1.34 software.
Genotype analysis of 2129 G/T, +256 T/C, rs2664349 A/G
and rs2664352 C/T was performed with allele-specific fluorogenic
probes and the TaqManH technique. Primers and probes were
designed and synthesized by Applied Biosystems and provided as
an SNP Genotyping Assay Mix specific for each SNP. Probes were
labeled with the fluorophores, 6-carbofluorescein (FAM) or VIC
(Table 1), and were minor groove binder (MGB) probes. PCR was
carried out in a 20-mL volume containing 10 ng of genomic DNA,
10 mL of TaqManH Genotyping Master Mix (Applied Biosystems)
and 1 mL of TaqManH SNP Genotyping Assay Mix 206(Applied
Biosystems). Thermal cycling conditions were 95uC for 10 min,
then 40 cycles of 92uC for 15 sec and 60uC for 1 min in the ABI
PRISM 7000 (Applied Biosystems). The genotypes were deter-
mined by reading the fluorescent signal of FAM and VIC from the
end-products.
Real-time quantitative PCR (qPCR)
RNA from each sample extract was reverse-transcribed into
cDNA by using 2 mg of total RNA, Superscript II reverse
transcriptase, and random hexamer primers (Invitrogen) according
to the supplier’s protocol. Realtime PCR was performed on an ABI
Prism 7000 (Applied Biosystems, Courtaboeuf, France) using the
following protocol: initial denaturation (10 min at 95uC), then two-
step amplification program (15 s at 95uC followed by 1 min at 60uC)
repeated40times.Meltcurve analysis wasused tocheckthat a single
specific amplified product was generated. Reaction mixtures
consisted of 25 ng cDNA, SYBR Green 26 PCR Master Mix
Table 1. Single-nucleotide polymorphisms (SNPs) studied in
the MMP2, MMP14, and MMP16 genes.
Gene Genomic location Reference Alleles Fluorophores*
MMP2 21306 rs243865 C/T -
MMP14 2129 rs1003349 G/T G: VIC
T: FAM
MMP14 +256 rs1042703 T/C T: FAM
C: VIC
MMP14 +6762 rs2236302 C/G -
MMP14 +6802 rs1042704 G/A -
MMP14 +6926 rs2236303 C/T -
MMP14 +7131 rs2236307 T/C -
MMP16 +39811 rs2664349 A/G A: VIC
G: FAM
MMP16 +43827 rs2664352 C/T C: VIC
T: FAM
*Allele-specific fluorogenic probes used for genotyping with the TaqManH
technique.
doi:10.1371/journal.pone.0003188.t001
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GTGGTGTAC-39) and reverse primers (59-CTTCTGCCCAGT-
TAATGCATAGC-39) in a reaction volume of 25 ml. Primers were
designed using Primer Express software (Applied Biosystems). Real-
time quantification was performed by measuring the increase in
fluorescence caused by the binding of SYBR Green dye to double-
stranded DNA at the end of each amplification cycle. Relative
expression was determined by using the DDCt (threshold cycle)
method for normalized samples (DCt) relative to a calibrator sample,
according to the manufacturer’s protocol. Each PCR run included a
no-template control and a sample without reverse transcriptase. All
measurements were performed in triplicate.
Statistical analysis
To test whether the genotypes were in Hardy-Weinberg
equilibrium, we compared the observed genotype frequencies with
their expected frequencies at equilibrium, based on the Chi2 test.
Odds ratios (Ors) and p values adjusted for birth weight and ethnic
origin, obtained by logistic regression, were calculated to test the
association between the genotypes and BPD. Differences between
treatment groups in animal studies were evaluated with the Kruskal-
Wallis non-parametric test for multiple group comparisons, and the
Mann-Whitney U test for two-group comparisons.
Results
Study population
All infants were inborn, and received prophylactic surfactant in
the delivery room. Of the 284 neonates initially enrolled, 21 died
before 36 weeks PMA and were not included in the analysis.
Death was mainly due to severe neurological or infectious
complications. Among survivors, 48% had histologically defined
chorioamnionitis, 8% had bacteriologically proven maternofetal
infection, 76% received medical treatment for persistent ductus
arteriosus, 16% had bacteriologically proven postnatal sepsis, and
only one had air leak. Ninety-two percent of mothers had received
partial or complete steroid treatment before delivery. Forty-five
(17%) of the other 263 infants still needed oxygen supplementation
at 36 weeks PMA and were thus diagnosed with BPD. As
expected, the risk for BPD was significantly associated with
birthweight, persistent ductus arteriosus, postnatal sepsis, and
chorioamnionitis in univariate analysis (Table 2). Birthweight was
the only significant risk factor for BPD in multivariate analysis
(OR (95%CI)=0.996 (0.993–0.998); p=0.0017), and was there-
fore used as adjustment factor in genetic analysis.
Genotyping
The observed genotype frequencies did not deviate from Hardy-
Weinberg equilibrium. The genotype distribution of 7 of the 9
studied SNPs was significantly influenced by ethnic origin. Table 3
shows the frequency of BPD in infants with different genotypes.
After adjustment for birth weight and ethnic origin, the TT
genotype of MMP16 C/T and the GG genotype of MMP16 A/G
were found to be associated with a significantly lower risk of BPD
(Table 3). The T allele frequency of the MMP16 C/T
polymorphism was 50% in infants without DBP, as compared
with only 34% in infants with BPD (p=0.01). Similarly, the G
allele frequency of the MMP16 A/G polymorphism was found to
be significantly higher in infants without BPD than in those with
BPD: 37% versus 23%, respectively (p,0.03). Twin cases did not
Table 2. Univariate analysis of perinatal factors potentially influencing the risk of BPD.
Variable Infants with BPD/total (%) OR 95% CI P
Sex Female 20/132 (15) 1
Male 25/131 (19) 1.321 0.693–2.518 0.398
Ethnicity* European 19/97 (20) 1
North Africa 3/23 (13) 0.616 0.166–2.289 0.469
Sub-Saharan Africa 15/103 (15) 0.700 0.333–1.470 0.346
Other 8/40 (20) 1.026 0.408–2.583 0.956
Birth weight (100 g) 0.585 0.453–0.755 ,0.0001
Gestational age (wk) 0.804 0.590–1.096 0.167
Maternofetal infection No 41/237 (17) 1
Yes 2/21 (10) 0.503 0.113–2.245 0.368
Persistent ductus No 4/63 (6) 1
arteriosus1 Yes 39/195 (20) 3.687 1.263–10.770 0.017
Surgical treatment for No 32/219 (15) 1
ductus arteriosus Yes 11/39 (28) 2.296 1.040–5.068 0.040
Chorioamnionitis No 22/105 (21) 1
Yes 7/99 (7) 0.287 0.117–0.707 0.007
Postnatal sepsis No 32/218 (15) 1
Yes 12/41 (29) 2.405 1.113–5.196 0.025
Antenatal steroid No 3/21 (14) 1
therapy Partial 16/76 (21) 1.600 0.419–6.117 0.492
Complete 25/163 (15) 1.087 0.298–3.966 0.899
*Ethnic group was based on the common origin of both parents; newborns whose parents had different ethnic origins were classified as ‘‘other’’ ;
1Need for medical treatment
doi:10.1371/journal.pone.0003188.t002
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pairs, 1 monozygotic twin pair, and 4 triplet pairs were present.
Adjusted results for multiple births still identified TT and GG
genotypes as significantly associated to a lower risk of BPD
(p,0.02 and ,0.05, respectively).
Twenty-one infants died before 36 weeks of post-menstrual age.
Among clinical factors significantly associated to the development
of BPD in our population (Table 2), only birthweight (747636 g)
was found to significantly differ in deceaded infants from alive
infants without BPD. None of SNPs were associated to death.
When evaluating the composite outcome of death or BPD by
36 weeks of post-menstrual age, adjusted OR associated to GG
and TT genotypes were 0.406 (0.126–1.310; p=0.1315) and
0.447 (0.184–1.085 ; p=0.0753), respectively.
Power of our study results from the effect of SNP on disease (odds
ratio), the sample size (n) and the type I error risk (alpha). When
consideringamultiplicativemodelforthealleleassociatedwithBPD,
and the 45 children with BPD among 263 preterm infants recruited
inthisstudy,foralpha=5%,thepowerofthe one-sidedtesttodetect
an association between BPD and an allele is equal to 99% with a C/
Tfrequencyof0.50andanoddsratioof3.8orisequalto98%witha
G/A frequency of 0.37 and an odds ratio of 3.3. If we take into
account that the two SNPs found positively associated to BPD were
tested among 9 candidates, groupsample sizes of 45 and218 achieve
82% power for each gene to detect a true allelic difference of at least
0.15 and with a false discovery rate of 0.05.
MMP2 level in tracheal aspirates
The mean MMP2 protein content and activity did not differ
significantly on day 0 between infants who subsequently developed
BPD and those whodid not (Table4). However, second samples had
significantly higher MMP2 contents and higher levels of activated
MMP2 in BPD infants. The pattern of change in the activated
MMP2 fraction differed significantly according to BPD status, with
lower levels at birth in BDP infants, followed by a steep increase
during the first days oflife(p=0.0001, repeated measures ANOVA).
A significant association was found between polymorphisms in the
MMP16 gene and the activated MMP2 fraction in second samples,
but not in first samples (day 0) (Figure 1). No significant association
was found between the MMP2 or MMP14 genotypes and MMP2
activity in tracheal aspirates (data not shown).
MMP16 protein content in human samples
Given this association between the MMP16 genotype and
MMP2 activation, we used immunoblot to determine MMP16
protein content in supernatants of tracheal aspirates from infants
Table 3. SNP genotypes and frequency of BPD in infants; odds ratio and P values for the association between genotype and BPD,
after adjustment for birth weight and ethnic origin, using logistic regression.
Gene and position of SNP Genotype Infants with BPD/total (%) Adjusted OR 95% CI P
MMP2 CC 30/162 (19) -
21306 CT 11/44 (25) 1.123 0.446–2.828 0.806
TT 0/4 (0) NC
MMP14 GG 25/141 (18)
2129 GT 12/82 (15) 0.877 0.395–1.946 0.747
TT 2/21 (10) 0.499 0.103–2.423 0.388
MMP14 TT 30/179 (17) -
+256 TC 9/59 (15) 0.667 0.280–1.587 0.359
CC 0/7 (0) NC
MMP14 CC 31/178 (17)
+6762 CG 9/67 (13) 0.905 0.377–2.175 0.823
GG 2/10 (20) 1.395 0.249–7.822 0.705
MMP14 GG 34/203 (17)
+6802 GA 8/48 (17) 0.823 0.328–2.062 0.678
AA 0/4 (0) NC
MMP14 CC 29/163 (18)
+6926 CT 10/78 (13) 0.684 0.290–1.613 0.386
TT 3/14 (21) 1.109 0.268–4.579 0.886
MMP14 TT 21/131 (16)
+7131 TC 17/96 (18) 1.239 0.581–2.644 0.579
CC 4/28 (14) 1.327 0.387–4.553 0.653
MMP16 AA 25/113 (22)
+39811 AG 16/100 (16) 0.668 0.320–1.395 0.282
GG 2/35 (6) 0.208 0.044–0.978 0.047
MMP16 CC 19/76 (25)
+43827 CT 19/112 (17) 0.579 0.270–1.241 0.160
TT 5/60 (8) 0.244 0.080–0.744 0.013
NC=not calculated
doi:10.1371/journal.pone.0003188.t003
MMP16 Polymorphisms in BPD
PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3188with homogenous genotypes, namely GG and TT (n=8) or CC
and AA (n=9). A single 45-kD band was observed in every case.
Tracheal aspirates from infants with the GG-TT genotype
contained three times less MMP16 protein than those from
infants with the CC-AA genotype (Figure 2).
MMP16 protein expression was also determined in lung tissue
from eight deceased fetuses without lung disease, sampled between 13
and 35 weeks of pregnancy (Figure 3A). Three bands were observed,
at 65 kD, 45 kD, and ,35 kD. While expression of the 65-kD band
remained stable during fetal life, expression of the lower-molecular-
weight species rose sharply from the 30th week of pregnancy.
MMP16 expression in rat lung
Expression profile of MMP16 mRNA and protein from fetal
life to adulthood. The MMP16 mRNA level was evaluated in
developing rat lung from fetal day 18 (canalicular stage) to
adulthood. Gene expression changed little until postnatal day 1,
then increased gradually to about five times the fetal level on day 14,
remained elevated until day 24, and returned to an extremely low
level (lower than before birth) inadulthood (Figure 3B). As in human
tissue, immunoblotting showed three bands, with molecular weights
of 65 kD, 45 kD, and ,35 kD. Expression of all the bands increased
from postnatal day 5 to postnatal day 21, but the strongest increase
was observed for the 65 kD band (Figure 3C). Confirmatory
experiments were performed with quantification of protein
expression in 4 individual samples at days 1, 7, and 21. A
significant increase was found for the 65 kD protein (Table 5). The
Figure 1. Association between MMP16 polymorphisms (A: rs2664349 A/G; B: rs2664352 C/T) and the size of the activated fraction
of MMP2 measured in tracheal aspirates. Aspirates were collected immediately after birth (open bars), and between 1 and 3 days of life (closed
bars). * p,0.05 in post-hoc analysis.
doi:10.1371/journal.pone.0003188.g001
Table 4. MMP2 ELISA values and zymographic analysis of
MMP2 activity in tracheal effluents of premature newborns.
BPD 2 BPD + p
Initial sample (H0) n=126 n=22
MMP2 content (ng.mL-1) 1.3660.06 1.4260.08 NS
Total activity (AU.mL-1) 2.8860.06 3.0360.09 NS
Activated form (AU.mL-1) 1.9660.07 1.8460.12 NS
Activated form (% of total) 19.761.5 9.862.0 0.009
Second sample (day 1 to 3) n=89 n=16
MMP2 content (ng.mL-1) 1.2960.04 1.5160.09 0.034
Total activity (AU.mL-1) 2.7260.06 3.0060.08 0.054
Activated form (AU.mL-1) 1.8260.07 2.2960.09 0.009
Activated form (% of total) 19.061.6 26.064.3 NS
Infants were ascribed to one of two subgroups according to their BPD
phenotype. Values are means6SEM and were log transformed to respect a
normal distribution.
doi:10.1371/journal.pone.0003188.t004
Figure 2. MMP16 immunoblots of tracheal aspirate superna-
tants from infants with the MMP16 AA-CC (lanes a–c) and GG-
TT (lanes d–f) genotypes. Upper: a 45-kDa band was clearly
identified in AA-CC infants but was barely visible in GG-TT infants.
Lower: densitometric analysis (arbitrary units [A.U.]) in 9 AA-CC infants
and 8 GG-TT infants, showing a significant difference in the MMP16
level (Mann Whitney p,0.02).
doi:10.1371/journal.pone.0003188.g002
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difference was not significant.
Effects of hyperoxia and dexamethasone on MMP16 gene
expression in postnatal rat lung. In newborn rats exposed to
hyperoxia for 7 days, the MMP16 gene expression level (Figure 4A)
was about 60% lower than in controls. Similarly, dexamethasone
caused a dose-dependent fall in the MMP16 mRNA level. MMP16
gene expression fell by 30% and .50%, respectively, with the 0.1
and 0.5 mg/kg/d dexamethasone dosages (Figure 4B). Protein
changes, evaluated by immunoblotting, were concordant with
Figure 3. Developmental pattern of MMP16 gene and protein expression in control lungs. A. Immunoblot of lung homogenates from
human fetuses without lung disease, at 11 to 36 weeks of gestation. B. Changes in the MMP16 mRNA expression level in rat whole lung tissue.
Expression was quantified by real-time PCR from fetal life (canalicular stage of development) to adulthood, in 3 to 5 individual lung samples per
stage. The birth level was arbitrarily given a value of 100. Values are means6SEM. * p,0.05 versus birth level. C. Immunoblot of lung homogenates
from control rats, from fetal life to adulthood.
doi:10.1371/journal.pone.0003188.g003
MMP16 Polymorphisms in BPD
PLoS ONE | www.plosone.org 7 September 2008 | Volume 3 | Issue 9 | e3188RNAchanges.Densitometryresults,expressed asapercentageofthe
control value, showed that the 65 kD form decreased to 2865%
(n=4 ; p,0.03) and to 4868% (n=4 ; p,0.03), after hyperoxia or
0.5 mg/kg/d dexamethasone, respectively. The changes in the 45
kD form (48615%, and 176632% of control values, respectively)
were not found to be significant.
Discussion
Genetic susceptibility to BPD was demonstrated in a recent
study of monozygotic and dizygotic twins [12]. After controlling
for covariates, genetic factors were shown to account for 53% of
the variance in the risk of BPD [12]. Genes encoding
multifunctional proteins in the distal lung are prime candidates
for determining susceptibility to BPD.
We sought links between BPD and SNPs in three MMP genes.
We found a significant association between two SNPs in the
MMP16 gene and BPD outcome, even after adjustment for birth
weight and ethnic origin. The MMP16 genotype also influenced
the size of the activated MMP2 fraction in the infants’ tracheal
aspirates. In addition, MMP16 gene expression was high during
normal newborn rat lung alveolarization, and was markedly
reduced by insults that arrested alveolarization.
Heterogeneous management of preterm infants hampers genetic
analyses. Indeed, the frequency of BPD varies widely among
neonatal intensive care units, underlining the role of environmen-
tal factors. The prospective nature of our study helped to ensure
that newborns who did and did not subsequently develop BPD
received similar initial management. The rate of BPD was low
(17%), reflecting good control of external insults. Furthermore,
oxygen dependency at a postmenstrual age of 36 weeks was
diagnosed with a validated test [15].
No association was found between the risk of BPD and SNPs in
the MMP2 or MMP14 gene. The SNPs we selected have previously
been linked to human respiratory diseases, including COPD [14],
and lung cancer [19,20]. The proteinases produced by these two
genes play an important role in the control of distal lung
development [4,7–9]. MMP2 has also been implicated in the
pathogenesis of BPD [5,6]. In the present study, MMP2 content and
activity were measured in tracheal effluents. The main finding was
the association between the risk of BPD and the proportion of the
activated fraction of MMP2. Relative to infants who did not develop
BPD,infantswho developed BPD hada significantlysmaller fraction
ofactive MMP2at birth,but a larger fraction at the second sampling
time. These results support our previous findings [5]. They are also
in keeping with the early increase in the active MMP2 fraction
previously observed in the lungs of newborn rats exposed to
hyperoxia [21]. However, contrary to our previous findings, total
MMP2 activity did not differ on day 0 between neonates who
subsequently developed BPD and those who did not in this study.
Differences in the study populations might account for this apparent
discrepancy.Inthepresentstudytheneonatesweremorepremature,
were all sampled within minutes after birth, and all received
prophylactic surfactant administration. No association was found
between the MMP2 and MMP14 genotypes and MMP2 levels in
tracheal aspirates. By contrast, the MMP16 genotype was associated
both with the risk of BPD and with the level of MMP2 activity in
tracheal aspirates. In keeping with our observation that BPD was
associated with an elevated active fraction of MMP2, the MMP16
genotypesassociated with a lowerriskofBPD,i.e. GGand TT, were
also associated with lower active fractions of MMP2.
MMP16, also called MT3-MMP, is very similar to MMP14 in
both structure and function. It is present in membranes as an
active 65-kD form, and has recently been shown to be shed in a
32- to 35-kD soluble form that retains its ability to activate MMP2
[22]. A 45-kD soluble form of MMP16 has also been suggested to
be formed by alternative splicing of mRNA [11], the splicing point
potentially lying in the hemopexin-like domain. It was recently
suggested that the two forms of this protein could play distinct
Table 5. Densitometric analysis (arbitrary units6SEM) of
immunoblots of lung homogenates from control rats at three
postnatal ages: day 1, day 7, and day 21 (n=4 at each stage).
Day 1 Day 7 Day 21
65 kD 7266223 12776314 23086385*
45 kD 13746282 7576193 1802683
Ponceau S stain was used as loader control. Normalization of immunoblots was
achieved through the run of a common sample.
*p,0.05 as compared with day 1.
doi:10.1371/journal.pone.0003188.t005
Figure 4. Changes in lung MMP16 mRNA expression in
newborn rats exposed to insults associated with alveolar
developmental arrest. A: Exposure to hyperoxia (O2.95%) from
birth to day 6; B: Daily administration of dexamethasone from birth to
day 5 (two doses). Results are expressed as a percentage of the control
value. * p,0.05 in two-group comparisons.
doi:10.1371/journal.pone.0003188.g004
MMP16 Polymorphisms in BPD
PLoS ONE | www.plosone.org 8 September 2008 | Volume 3 | Issue 9 | e3188roles during embryogenesis. Indeed, Xenopus laevis embryos
injected with full-length MMP16 mRNA showed no significant
changes in the expression levels of the tissue-specific genes
encoding endodermin, chordin and muscle actin, whereas mRNA
for the soluble form of MMP16 reduced the expression of all three
marker genes. In addition, while full-length tethered MMP16
failed to alter gelatinase activity, a 50% increase occurred after
injection of the soluble form [23]. MMP16 was recently shown to
act as a major collagenolytic enzyme in bone and cartilage during
mammalian embryogenesis, with MMP16-deficient mice display-
ing delayed skeletal growth [24]. Although no genotype-related
abnormality is reported in lungs of adult mutant mice in the
international database resource for the laboratory mouse (http://
www.informatics.jax.org/external/ko/deltagen/1241.html), lung
development was not extensively studied in these mice. MMP16
is known to be expressed in the human lung [10]. Its role is largely
obscure, but it has been implicated in disease processes such as
idiopathic pulmonary fibrosis [25]. Our study is therefore the first
to provide strong evidence of MMP16 participation in normal and
abnormal lung development, in both newborn rats and premature
infants. In newborn rats, lung MMP16 gene expression is low
during the canalicular and saccular stages, and increases
significantly very close to the beginning of alveolarization, i.e.
postnatal day 4 [26]. Then, lung MMP16 gene expression peaks
on day 14 and remains elevated until day 24 of life, before falling
to very low levels in adulthood. MMP16 protein expression in rat
lung ran parallel to MMP16 gene expression, with a gradual
increase in both the presumed transmembrane and soluble forms
during alveolarization, and strong expression on day 21. The
results we obtained with homogenates of normal human fetus
lungs sampled at various stages were concordant with the results
we obtained in rats. We observed a clear increase in the expression
of the presumed soluble form as early as 30 weeks of human
pregnancy, i.e. just before the beginning of alveolarization [26].
Although these observations were gained from tissues collected
postmortem, these samples have previously been proven suitable
for evidencing developmental changes as well as differences
between normal and diseased lungs [17,27]. We found that the
pulmonary MMP16 expression profile differed from that of
MMP14 in lung fibroblasts from newborn rats. MMP14 gene
expression increased at the time of peak alveolarization but rapidly
returned to the basal level as early as 16 days of life [7]. Although
MMP16 is closely related to MMP14 in terms of its molecular
structure and tissue expression pattern [10,24], differences in the
expression profiles suggest that MMP16 is not merely functionally
redundant to MMP14. Alveolarization takes place between days 4
and 21 in rats and comprises two successive steps, namely
secondary alveolar septation from day 4 to day 14, and alveolar
wall thinning with fusion of the initially double capillary layer into
a single, central microvascular network from day 14 to 21 [26].
The different expression profiles of MMP14 and MMP16 suggest
primary involvement of the former in the first step and of the latter
in the whole process, including the second step.
The functional domains of MMP16 and MMP14 are not
interchangeable for pro-MMP2 activation and collagenolysis,
despite their similarities [28]. It was also shown recently that the
collagenolytic activity of MMP16 is complementary to that of
MMP14 in mice lacking both enzymes [24]. Further evidence
supporting the role of MMP16 as a significant controller of
alveolar growth/maturation comes from its down-regulation in
models of arrested of lung development. We found that hyperoxia
and dexamethasone, both of which impair alveolarization, strongly
reduced lung MMP16 gene expression in newborn rats. We also
observed a significant association between two polymorphisms in
the MMP16 gene and the risk of BPD in highly premature infants.
Despite strong evidence of genetic susceptibility to BPD [12], only
polymorphisms in the genes for glutathione-S-transferase-P1 [29],
surfactant protein-B [30], and TNF-a [31] have been identified as
possible genetic determinants. The functionality of the two SNPs
that we studied in the MMP16 gene remains to be determined.
They were chosen because they are tags for a haplotype in a gene
region that codes for the hemopexin-like domain and that might
be alternatively spliced [11]. The association we found between
the infants’ genotypes and both the MMP16 protein level and the
size of the activated MMP2 fraction in tracheal aspirates strongly
suggests that these polymorphisms have functional consequences,
although no definitive proof is given that the changes in MMP16
are causative of reduced MMP2 activation.. The premature
infants had a gestational age lower than 28 weeks, corresponding
to the early saccular stage of lung development. We found that
expression of the 45-kD soluble form of MM16 was low in human
fetal lung tissue. The TT and GG genotypes were associated with
a 3-fold lower 45-kD MMP16 protein content in tracheal aspirates
collected within 3 days after birth, and with a smaller MMP2
active fraction, in keeping with experimental results linking
expression of the soluble MMP16 form to the level of gelatinase
activity [23]. These genotypes were also found to be associated
with a significantly lower risk of BPD, suggesting that maintenance
of the physiologically low expression of the 45-kD soluble MMP16
isoform at this stage of lung development protects against BPD.
Apparent discrepancies between changes in MMP16 expression in
BPD infants and changes in animal models of arrested
alveolarization may be due to differences in time frame. Animal
experiments are models of arrested alveolar septation, a stage
associated to a strong physiological increase in MMP16 expres-
sion. Thus, in both BPD infants and animal models, altered distal
lung development is associated to opposite changes in MMP16
expression as those normally observed in the corresponding lung
development stage. It is also noteworthy that changes in protein
expression in animal models were found significant only for the
tissular 65 kD form. For evident reasons, we were not able to
evaluate this tissular form in human prematures. Changes in
balance between tissular and soluble forms may also contribute to
lung growth disorders.
In conclusion, we identify MMP16 as a possible new regulator
of lung alveolar development and provide evidence that MMP16
polymorphisms are associated with protection from bronchopul-
monary dysplasia in highly premature infants.
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